0 CHECKOUT

Francisella Tularensis Infections - Pipeline Review, H2 2015

  • ID: 3422693
  • August 2015
  • 45 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aradigm Corporation
  • Arno Therapeutics, Inc.
  • EpiVax, Inc.
  • MORE

Francisella Tularensis Infections - Pipeline Review, H2 2015

Summary

The report ‘Francisella Tularensis Infections - Pipeline Review, H2 2015’, provides an overview of the Francisella Tularensis Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aradigm Corporation
  • Arno Therapeutics, Inc.
  • EpiVax, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Francisella Tularensis Infections Overview

Therapeutics Development

Pipeline Products for Francisella Tularensis Infections - Overview

Pipeline Products for Francisella Tularensis Infections - Comparative Analysis

Francisella Tularensis Infections - Therapeutics under Development by Companies

Francisella Tularensis Infections - Therapeutics under Investigation by Universities/Institutes

Francisella Tularensis Infections - Pipeline Products Glance

Early Stage Products

Francisella Tularensis Infections - Products under Development by Companies

Francisella Tularensis Infections - Products under Investigation by Universities/Institutes

Francisella Tularensis Infections - Companies Involved in Therapeutics Development

Aradigm Corporation

Arno Therapeutics, Inc.

EpiVax, Inc.

Tetraphase Pharmaceuticals Inc.

Francisella Tularensis Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AR-12 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ciprofloxacin hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

francisella tularensis [strain SchuS4] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SRI-011225 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TP-271 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tularemia vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TuliVax - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Francisella Tularensis Infections - Recent Pipeline Updates

Francisella Tularensis Infections - Dormant Projects

Francisella Tularensis Infections - Dormant Projects

Francisella Tularensis Infections - Discontinued Products

Francisella Tularensis Infections - Product Development Milestones

Featured News & Press Releases

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12

Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases

Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Francisella Tularensis Infections, H2 2015

Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Francisella Tularensis Infections - Pipeline by Aradigm Corporation, H2 2015

Francisella Tularensis Infections - Pipeline by Arno Therapeutics, Inc., H2 2015

Francisella Tularensis Infections - Pipeline by EpiVax, Inc., H2 2015

Francisella Tularensis Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Francisella Tularensis Infections Therapeutics - Recent Pipeline Updates, H2 2015

Francisella Tularensis Infections - Dormant Projects, H2 2015

Francisella Tularensis Infections - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Francisella Tularensis Infections, H2 2015

Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Aradigm Corporation
Arno Therapeutics, Inc.
EpiVax, Inc.
Tetraphase Pharmaceuticals Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.